Previous Article | Next Article 
Mol Cell Biol, February 1998, p. 1042-1048, Vol. 18, No. 2
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Nonimmunoglobulin Transgene and the Endogenous Immunoglobulin µ Gene Are Coordinately Regulated by Alternative RNA Processing
during B-Cell Maturation
Rebecca L.
Seipelt,1,
Brett T.
Spear,1,2,3
E. Charles
Snow,1,3 and
Martha L.
Peterson1,2,3,*
Department of Microbiology and
Immunology,1
Department of Pathology and
Laboratory Medicine,2 and
The
Lucille Parker Markey Cancer Center,3 University
of Kentucky College of Medicine, Lexington, Kentucky 40536
Received 7 August 1997/Returned for modification 13 October
1997/Accepted 3 November 1997
 |
ABSTRACT |
The immunoglobulin (Ig) genes have been extensively studied as
model systems for developmentally regulated alternative RNA processing.
Transcripts from these genes are alternatively processed at their 3'
ends to yield a transcript that is either cleaved and polyadenylated at
a site within an intron or spliced to remove the poly(A) site and
subsequently cleaved and polyadenylated at a downstream site. Results
obtained from expressing modified genes in established tissue
culture cell lines that represent different stages of B-lymphocyte
maturation have suggested that the only requirement for regulation is
that a pre-mRNA contain competing cleavage-polyadenylation and splice
reactions whose efficiencies are balanced. Since several non-Ig
genes modified to have an Ig gene-like structure are regulated in
cell lines, Ig-specific sequences are not essential for this control.
This strongly implies that changes in the amounts or activities of
general RNA processing components mediate the processing regulation.
Despite numerous studies in cell lines, this model of Ig gene
regulation has never been tested in vivo during normal lymphocyte
maturation. We have now introduced a non-Ig gene with an Ig gene-like
structure into the mouse germ line and demonstrate that RNA from the
transgene is alternatively processed and regulated in murine
splenic B cells. This establishes that the balance and arrangement of
competing cleavage-polyadenylation reactions are sufficient for RNA
processing regulation during normal B-lymphocyte development. These
experiments also validate the use of tissue culture cell lines for
studies of Ig processing regulation. This is the first transgenic mouse produced to test a specific model for regulated mRNA processing.
 |
INTRODUCTION |
The immunoglobulin (Ig) genes were
among the first discovered to encode more than one gene product; the Ig
pre-mRNA is differentially processed at its 3' end into mRNAs that
encode secreted and membrane-associated forms of the Ig protein
(1, 8, 30). The mRNA encoding the secreted IgM protein (µs
mRNA) is produced when the precursor RNA is cleaved and polyadenylated
at the promoter-proximal µs poly(A) site. If the precursor RNA is
instead spliced between the Cµ4 and M1 exons, which removes the µs
poly(A) site, and is cleaved and polyadenylated at the downstream µm
poly(A) site, the mRNA encoding the membrane-associated IgM protein
(µm mRNA) is produced. During B-lymphocyte maturation from a resting
B cell to an activated B cell or plasma cell, there is a shift in the relative amounts of µs and µm mRNAs produced; plasma cells express relatively more µs mRNA than B cells. How this and other Ig genes are
regulated by alternative RNA processing during B-cell maturation has
been studied mainly by introducing modified Ig genes into cell lines
representing different stages of B-cell maturation (reviewed in
reference 26).
By analyzing the processing patterns of modified µ genes, it has been
established that cleavage-polyadenylation at the µs poly(A) site and
splicing between Cµ4 and M1 are mutually exclusive RNA processing
reactions whose efficiencies are suboptimal but balanced. The balance
between the efficiencies of the reactions, but not their suboptimal
nature, is required for regulation; if the efficiencies of both
reactions are improved, regulation is maintained. However, if either
reaction is made too strong relative to the other, only one RNA is
produced from the modified gene in all cell types (24, 29).
These observations led us to propose that a µ gene-like structure,
with competing cleavage-polyadenylation and splicing reactions, is
sufficient for µ processing regulation. This predicts that
alternative RNAs from a gene with a similar arrangement of processing
signals would be regulated like µ RNA in B cells and plasma cells. We
confirmed this prediction by demonstrating that RNAs from two different
non-Ig genes modified to have a poly(A) site within an intron are
indeed regulated when expression in B-cell and plasma cell lines is
compared (25). Thus, changes in RNA processing patterns
during lymphocyte maturation must be mediated, at least in part, by
general processing factors rather than gene-specific factors.
In the past, studies of Ig gene regulation have been conducted by using
tissue culture cell lines derived from mouse lymphomas, myelomas, and
plasmacytomas. The stage of lymphocyte development that each cell line
most closely resembles is determined based on the presence of specific
cell surface molecules and their Ig secretion status (see, e.g.,
references 15 and 17). Over the years and in a number of different laboratories, more than 16 different
cell lines representing B-cell and plasma cell stages have been
transfected with Ig genes, both stably and transiently. While the exact
µs/µm,
s/
m, or
s/
m mRNA expression ratio varied among
cell lines and experiments, this ratio is always higher in cells of the
plasma cell stage than in cells of the pre-B- and B-cell stages.
Therefore, tissue culture cells have been considered a valid system
with which to study the mechanism regulating alternative processing of
Ig RNA. Nevertheless, tissue culture cell lines, since they are derived
from tumors and are maintained in continuous culture in vitro, are not
normal lymphocytes. In fact, the experimental results obtained from
cell lines and from resting and activated natural mouse B cells differ
with respect to increases in the rate of Ig gene transcription
initiation during lymphocyte maturation (11, 14, 16, 36).
The model we have proposed for µ regulation, i.e., that a µ gene-like structure is required and that changes in general processing
factors mediate the alternative processing, suggests a very different
future experimental approach than models that propose µ gene-specific
sequences. Therefore, we felt that it was essential to validate this
model by using a more natural experimental system.
Transgenic-mouse technology is a powerful tool that has been used to
gain insight into protein function, immunological responses, and
transcriptional regulation of gene expression (12). However, this technology has been used only once to address a question of
regulation at the level of alternative RNA processing: a transgenic mouse was produced to identify the non-cell-type-specific mRNA processing pattern of a ubiquitously expressed calcitonin/calcitonin gene-related peptide (CGRP) transgene (6). Most tissues in this mouse expressed calcitonin mRNA; CGRP mRNA expression was primarily restricted to neurons. The authors concluded that the CGRPprocessing pathway requires a tissue-specific cellular
environment, while production of calcitonin mRNA is the default or
nonregulated pathway. We describe here transgenic mice carrying a
non-Ig gene, the modified class I major histocompatibility complex
(MHC) gene Dd
s (25), that is
properly regulated in tissue culture cell lines to test our model that
a gene with balanced competing cleavage-polyadenylation and splice
reactions will be regulated during normal lymphocyte maturation.
Transgene mRNA processing should mimic the endogenous µ gene
mRNA processing during normal B-cell differentiation if the balanced
competition model holds true in nontransformed cells. In addition,
since the transgene is expressed in many tissues, we can assess the
contributions that unique cellular environments make to the expression
patterns of genes with competing splice and cleavage-polyadenylation
reactions.
 |
MATERIALS AND METHODS |
Transgene construction, preparation, and injection.
To
construct the transgene Dd
sTG (Fig.
1), a 2.7-kb
EcoRI-BamHI fragment containing the
Dd promoter (10) was first cloned
into EcoRI-BamHI-cut pGEM4Z (Promega) to obtain
the plasmid pGEM4Z-2.7. Next, a 4.5-kb
BamHI-HindIII fragment containing the
DdBsm(H)
s structural gene (25) was
ligated into BamHI- and HindIII-cut pGEM4Z-2.7 to obtain Dd
sTG.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Structure of the endogenous µ gene compared to that of
the Dd s transgene. The transgene was designed
to have processing options similar to those in the µ gene, i.e., a
poly(A) site (A) in competition with a splice reaction (angled lines
above). Two RNAs are processed from each of these genes. Large solid
boxes, common exons; open boxes, "exons" ending with a poly(A) site
that are unique to poly(A) or µs mRNA; hatched boxes, exons that are
unique to RNA that is spliced to remove the competing poly(A) site;
smaller stippled boxes, transcriptional control regions.
|
|
The DNA fragment containing the transgene was isolated from the vector
sequence by digestion with
EcoRI and
HindIII
followed
by agarose gel electrophoresis; the fragment was further
purified
by cesium chloride ultracentrifugation and dialysis. This DNA
was checked for quantity and quality by agarose gel electrophoresis
and
diluted to 5 ng/µl prior to injection. Fertilized (C3H × C57/BL6)F
1 eggs were injected and surgically implanted into
pseudopregnant
ICR/HSD females by Michael Green at the University of
Kentucky
Transgenic Mouse Facility as described previously
(
13).
Transgenic-animal screening.
Two to 3 weeks after birth,
pups were screened for transgene integration by Southern blot analysis
of DNA obtained from tail biopsies (18). DNAs were digested
with PstI and probed with a DNA fragment that hybridizes to
both the transgenic and endogenous
s poly(A) sites, producing a
2.4-kb endogenous fragment and a 1.7-kb transgenic fragment (data not
shown). Individual lines were established from 3 of the 11 originally
obtained transgenic founder mice. Imaging analysis of Southern blots
allowed us to estimate that the 888 line has 20 copies, the 911 line
has 6 copies, and the 916 line has 4 copies of the transgene (data not
shown).
Preparation of primary B cells.
Splenocytes from 6- to
8-week-old transgenic littermates were isolated and treated with
anti-Thy 1.2 antibodies (hybridoma HO13-4.6; ATCC TIB 99), L3T4
antibodies (hybridoma RL-172/4) (5), and baby rabbit
complement (Pel Freez, Inc., Brown Deer, Wis.) to remove T cells.
High-density resting B cells isolated from the 70-60% interface of
Percoll buoyant density gradients (Pharmacia LKB Biotechnology,
Piscataway, N.J.) (7) were washed and diluted to 5 × 106 cells per ml for bulk culture and to 2 × 106 cells per ml for plating in RPMI 1640 medium containing
50 µM 2-mercaptoethanol, 24 mM sodium biocarbonate, 100 U of
penicillin and streptomycin (Sigma) per ml, 2 mM glutamine, and 50 µg
of gentamicin (BioWhittaker, Walkersville, Md.) per ml, with 10% heat-inactivated fetal calf serum (Sigma). Where indicated,
lipopolysaccharide (LPS) from Salmonella enteritidis (Sigma)
was used at 50 µg per ml. Untreated cells usually were harvested
immediately, while treated cells were harvested after 72 h in
culture. In two experiments, treated cells were cultured for 48 h;
this did not influence the RNA expression data.
Primary B cells were assayed for DNA synthesis by
[
3H]thymidine uptake. B cells were plated at 2 × 10
5/ml in 96-well plates. Six hours prior to harvest, 1 µCi of [
3H]thymidine in balanced salt solution (ICN
Pharmaceuticals Inc.,
Costa Mesa, Calif.) was added to each well. Cells
were harvested
onto glass fiber filters, and
[
3H]thymidine incorporation was measured with a
scintillation counter.
Stimulated cells incorporated at least 100-fold
more [
3H]thymidine than untreated cells (data not shown).
Carbon tetrachloride liver treatment.
Transgenic
littermates, aged 6 to 8 weeks, were injected intraperitoneally with 50 µl of 100% mineral oil (Sigma) or 10% carbon tetrachloride-90%
mineral oil (J. T. Baker, Phillipsburg, N.J.). Animals were
sacrificed at 48 or 72 h postinjection and their liver tissues
were removed for RNA analysis; there was no difference in the RNA
expression data for these two time points.
RNA preparation and analysis.
Primary B cells were harvested
by centrifugation; tissues were collected by dissection. RNA was
isolated by using Trizol reagent as directed by the manufacturer (Gibco
BRL).
S1 nuclease analysis was performed as detailed previously (
25,
29). For analysis of µ RNA, 100 µg of RNA (a combination
of
specific and carrier RNAs) was hybridized at 50°C for 16 to
20 h
with a 640-bp
PstI-
HindIII µ gene fragment,
32P labeled at its 3' end, that distinguishes messages
spliced at
the Cµ4 exon from those cleaved and polyadenylated at the
µs poly(A)
site (Fig.
2B). After
hybridization, samples were diluted with
0.45 ml of S1 buffer and
digested with 40 U of S1 nuclease at
42°C for 30 min. For analysis of
transgene RNA, 50 µg of RNA (a
combination of specific and carrier
RNAs) was hybridized at 50°C
for 16 to 20 h with a 648-bp
BanI-
AccI
Dd
s gene
fragment,
32P labeled at its 3' end, that distinguishes
transcripts spliced
at exon 3 from those cleaved and polyadenylated at
the

s poly(A)
site (Fig.
2B). After hybridization, samples were
diluted with
0.225 ml of S1 buffer and digested with 40 U of S1
nuclease at
37°C for 30 min. DNA fragments protected from S1 nuclease
digestion
were separated on 6% polyacrylamide-7 M urea gels. The gels
were
dried, and the fragments were quantitated with an Ambis
Radioanalytic
Imaging System.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of endogenous µ and transgene RNAs in
response to LPS treatment. (A) Small resting splenic B lymphocytes
isolated from three different lines of transgenic mice, 888, 911, and
916, were treated with LPS for 72 h (+) and compared to nontreated
resting cells ( ). RNAs from these cell populations were isolated, and
expression of the endogenous µ gene (Cµ) and
Dd transgene (Dd tg) was analyzed by
S1 nuclease protection with the probes diagrammed in panel B. The
positions of the probes and the fragments protected by the
cleaved-polyadenylated RNA (pA), the spliced RNA (splice), and the
endogenous class I MHC gene (Db/k) are shown.
(B) Diagram of the S1 nuclease protection probes that distinguish
alternatively processed RNAs. For the Dd tg
probe, the triangle indicates the 18-nucleotide insertion into the
transgene that distinguishes it from the closely related endogenous MHC
Db/k mRNA. P, PstI; H,
HindIII; Bn, BanI; Ac, AccI. (C)
Quantitation of the regulation index (pA/splice ratios for cells
treated with LPS divided by pA/splice ratios for cells not treated with
LPS) for individual preparations of B cells from the transgenic mouse
lines indicated. TG, transgene.
|
|
 |
RESULTS |
The class I MHC Dd gene was modified
previously to contain a poly(A) site within the third intron so that
its structure was similar to that of the Ig µ gene; a 184-bp fragment
containing the
s poly(A) site was inserted into the third intron to
compete with the exon 3-to-exon 4 splice reaction (Fig. 1). Although
the
s site is from the regulated Ig
gene, we previously
established that sequences within the secreted poly(A) sites are not
specifically required for regulation, because both the µm and simian
virus 40 late poly(A) sites could substitute for the µs poly(A) site (29). Two alternative mRNAs were produced from this gene,
and their expression was regulated when compared in B-cell and plasma cell lines; like µ mRNA, relatively more spliced RNA was produced in
B cells (25). Twelve different poly(A) sites have been
placed into this Dd gene; expression from all of
these chimeric genes is regulated in cell lines (23). The
Dd
s gene also has an 18-bp insert in exon 3 to distinguish it from the endogenous Dd gene.
In the cell lines, the Dd
s gene was expressed
from the Ig
promoter linked to the simian virus 40 enhancer. So
that it would be more widely expressed in the mouse, the
Dd
s gene was cloned back under the control of
the natural Dd transcriptional control elements.
Previous studies have shown that this Dd gene
fragment is expressed similarly to the endogenous
Dd gene in transgenic mice (3).
Genomic DNA obtained from tail biopsies was used to determine transgene
integration into the mouse genome and to screen for germ line
transmission to progeny.
mRNA processing in LPS-treated transgenic B cells.
High-density resting splenic B cells isolated with Percoll buoyant
density gradients can differentiate in culture to antibody-secreting cells upon treatment with LPS. LPS stimulates resting B cells both to
proliferate and to differentiate along the path towards a plasma cell
fate, and this is a standard procedure used to study molecular events
that occur during these processes (see, e.g., references
19 and 36). In such bulk cultures
of resting cells, approximately 25% of the cells respond to the LPS
stimulation as measured by limiting dilution (35). The
µs-to-µm mRNA expression pattern gradually changed from
predominantly µm RNA at time zero of culture to approximately 90%
µs mRNA by 72 h of treatment (19). We measured the
µs/µm mRNA ratio from the endogenous µ gene in the resting
transgenic B cells and in transgenic B cells stimulated for 72 h
with LPS to monitor the resting and activated states of the cells. We
then measured the pA/splice expression pattern of the transgene RNA in
these B-cell populations to determine whether it was able to respond to
the changes that occurred in the RNA processing environment within
these cells.
Resting splenic B cells isolated from each of the three transgenic
mouse lines were either harvested or cultured with LPS.
RNAs from these
cell populations were analyzed for endogenous
µ mRNA processing by S1
nuclease protection analysis (Fig.
2A,
upper panel). In each of the
experiments shown, the µs/µm RNA
expression ratio was seen to
increase dramatically in the presence
of LPS, as has been seen
previously (
19), and indicated that
the LPS treatment was
effective. The regulation index, or change
in the µs/µm (pA/splice)
mRNA ratio from resting to treated B
cells, ranged from 7 to 12 (Table
1; Fig.
2C). This variability
is likely
due to minor differences in the activation states of
the high-density B
cells and the efficacy of the LPS treatment.
These results also
indicate that the presence of the transgene
did not adversely affect
B-cell development with respect to µ
mRNA processing.
After determination of the effectiveness of the LPS treatment in each
experiment, the transgene RNA processing patterns were
analyzed by S1
nuclease protection with RNAs from the resting
and LPS-treated B cells
(Fig.
2A, lower panel). In all three transgenic
lines, the pA/splice
RNA expression ratio increased upon LPS treatment
(Fig.
2A, upper
panel). In each of the eight experiments, there
was relatively more pA
RNA in the LPS-treated cells than in the
resting B cells for both the
endogenous µ gene and the
Dd
s transgene
(Table
1). The transgene regulation index ranged
from 3 to 6 and was
consistently about half of that of µ; when
there was a greater change
in the endogenous µ expression, there
was a parallel greater change
in the transgene expression (Table
1; Fig.
2C). All three transgenic
lines showed a similar change
in expression upon B-cell activation;
therefore, these results
must be independent of any positional effects
due to transgene
integration. The transgene was not expressed as well
in the 888
line (Fig.
2A, lower panel) (the transgene RNA signal was
much
lower relative to the endogenous MHC class I expression than the
other two lines); the lower level of transgene expression in the
888 line was seen in all tissues examined (data not shown). Therefore,
the
911 and 916 lines were used for additional experiments.
Transgene expression in mouse tissues.
When two different cell
types process the same pre-mRNA in different ways, it is generally
assumed that one cell type contains a trans-acting RNA
processing regulator and that the other cell type, lacking the
regulator, processes the pre-mRNA along a default pathway that is
dependent only on the general processing machinery (22).
This is clearly the case with the splice regulators that participate in
sex determination of Drosophila (see, e.g., reference 22). One approach that has been taken previously to
identify the cell type that contains trans-acting processing
regulators is to ectopically express the regulated gene (see, e.g.,
reference 6). It was assumed that cell types that
normally do not encounter the transcripts to be regulated will process
them along a default processing pathway. This then identifies the
regulated pathway and thus the cellular environment needed to process
the transcript in this way. Since the Dd
s
transgene is widely expressed in our mice, we analyzed transgene mRNA
processing in a number of different tissues in an attempt to identify
the regulated and default processing pathways for this gene. Tissues
were isolated from several mice of each transgenic line, and the RNAs
were analyzed by S1 nuclease protection (Fig. 3A; Table
2). The pA/splice expression ratio showed
variability between mice, but these deviations were not unlike those
observed in other transgene studies (32). The results did
not provide a clear answer to the question of whether tissues expressed
the transgene like resting B cells or like LPS-activated B cells. The
resting B-cell pA/splice expression ratio ranged from 0.19 to 0.43, while LPS-treated B-cell expression ratios ranged from 0.64 to 2.0 (Table 1). Mouse tissues had pA/splice expression ratios that ranged
from 0.08 to 1.2, overlapping both resting and LPS-activated B-cell
expression ratios, with more values falling into the resting B-cell
range (compare Tables 1 and 2). Since there was variability among
tissues and individual animals and among different preparations of
resting and LPS-activated B cells, it could be argued that a
distinction between regulated and default cannot easily be made for
this gene. This interpretation was also proposed to explain data
showing that nonlymphoid cells expressed variable ratios of µs and
µm mRNAs. While the µs/µm mRNA ratios in nonlymphoid cells were
more similar to those in a plasma cell than to those in a B cell,
because of the variability, we suggested that the B-cell and plasma
cell ratios were two along a continuum of possible processing patterns
rather than one being regulated and one not being regulated
(25). One major difference between our current experiments
and those published previously was that this study tested expression in
normal tissue which was generally not proliferating, while the others
examined expression in transformed cell lines which were continually
proliferating. To test whether any RNA processing differences were
related simply to cell proliferation, we examined transgene expression
during liver regeneration in vivo.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
Transgene expression in mouse tissues. (A) S1 nuclease
protection analysis of RNAs from the tissues labeled, from both a line
916 transgenic mouse (+) and a nontransgenic littermate ( ). (B) S1
nuclease protection analysis of liver RNAs from carbon
tetrachloride-treated animals (+) and from mineral oil-treated
littermates ( ). The probe is as diagrammed in Fig. 2B; protected
fragments are labeled.
|
|
Under normal conditions, the adult liver is a quiescent organ with a
vast majority of cells in the G
0 state. Mice treated
with
50 µl of 10% carbon tetrachloride (CCl
4), a drug that
specifically
kills hepatocytes in a dose-dependent manner, lose up to
75% of
their hepatocytes. Upon cell death, the remaining liver cells
proliferate to regenerate the entire liver within 7 to 10 days.
Between
48 and 72 h postinjection, hepatocytes proliferate maximally
(
2,
31). It was previously shown that at 60 h after
CCl
4 treatment, 32% of hepatocytes were proliferating, as
measured
by nuclear labeling (
31). This compares favorably
with the estimate
that about 25% of B cells respond to the LPS
treatment we used.
We examined transgene mRNAs in normal and
proliferating liver
cells; if the proliferative state of the cell
influences transgene
RNA processing, then we would expect to see a
difference between
the RNA ratios derived from mineral oil-treated
(nonproliferating)
and CCl
4-treated (proliferating) livers.
Transgenic littermates
were treated with either CCl
4 or
mineral oil (as controls); 48
or 72 h later these animals were
sacrificed and their livers were
removed. Visual inspection revealed
that only CCl
4-treated livers
were discolored and mottled
in appearance, consistent with areas
of necrosis and regeneration. RNA
from each liver was analyzed
for transgene expression by S1 nuclease
protection analysis (Fig.
3B). While there was a modest effect of liver
cell proliferation
on transgene processing in some of these experiments
(Table
3),
no consistent change could be
seen among the four experiments,
nor was the change as extensive as
that seen between resting and
LPS-treated B cells.
 |
DISCUSSION |
Previously we have shown that regulated µ mRNA processing
depends on both the balance and arrangement of the competing splice and
cleavage-polyadenylation reactions; no gene-specific sequences are
required for this regulation (25). Thus, it is likely that changes in general cleavage-polyadenylation and/or splicing components mediate µ regulation. Since this model is based on results obtained with established tumor cell lines, we felt it was essential to examine
this model in vivo during normal B-lymphocyte maturation. Now, using
transgenic mice, we show that a non-Ig gene modified to have balanced
competing splice and cleavage-polyadenylation reactions is regulated
similarly to the endogenous µ gene during LPS-stimulated B-cell
activation. These results establish that the balance and arrangement of
the two processing signals are indeed sufficient for RNA processing
regulation. Therefore, these studies validate previous and continuing
regulatory experiments using tissue culture cell lines; the data
generated in vivo is consistent with data generated from in vitro
tissue culture.
While the pA/splice RNA ratio for the transgene and the µ gene shift
in the same direction in resting and LPS-treated B cells, the
regulation index, which quantitates the change in this ratio, varies
among individual experiments. This is due to minor differences in the B
cells isolated from the mice. However, despite this variability, the
transgene regulation index is consistently about half of that of the
endogenous µ gene for each experiment (Fig. 2; Table 1). There are at
least two possible explanations for this 50% difference. One is that
there are specific sequences, either in the µ gene or in the
transgene, that contribute to the difference seen. The other
possibility is that the precise balance between the efficiencies of the
splice and cleavage-polyadenylation reactions affects the sensitivity
of a transcript to changes in the cellular environment. The latter idea
is supported by past experiments with closely related µ genes that
differ in the strengths of their splice and cleavage-polyadenylation
reactions (24, 27-29). The regulation indices of these µ gene derivatives in B-cell and plasma cell lines range from 2 to 22, a
much greater difference than that seen between the transgene and
endogenous µ gene in this study. These results with related µ genes
are more difficult to reconcile with the former explanation, i.e., the
presence or absence of specific sequences.
That gene-specific sequences are not required for regulation implies
that changes in the levels or activities of general processing factors
must mediate the change in RNA processing patterns. For the µ gene
this could mean changes in cleavage-polyadenylation factors, splicing
factors, or both. Indeed, we recently demonstrated that the level of
the polyadenylation component CstF-64, the 64-kDa subunit of cleavage
stimulation factor, is modulated between resting and LPS-stimulated B
cells and that overexpression of this protein affects endogenous µ RNA processing in a chicken B-cell line (33). This
experiment, along with others (20, 28), establishes that changes in cleavage-polyadenylation efficiency are an important component of µ processing regulation. However, while natural mouse B
cells respond to LPS stimulation with about a 10-fold increase in
CstF-64, consistent differences in the levels of this protein are not
seen in tissue culture cell lines (9). This implies that
there are additional mechanisms that contribute to µ processing regulation; possibilities include changes in the activity of
cleavage-polyadenylation components (9), changes in the
splice components (4), and changes in factors that affect
the communication between the splice and cleavage-polyadenylation
machinery (see, e.g., references 21 and
34). It is easy to imagine that changes in the
amounts or activities of general trans-acting factors,
relative to each other, can have dramatic effects on an RNA that can be
alternatively processed by competing reactions.
The idea that cell-specific levels of several different general factors
affect alternative RNA processing complicates the definition of the
classical regulated and default pathways wherein a specific
trans-acting factor affects processing choices, usually in
an all-or-none way. Indeed, we have not been able to clearly assign the
B cell or plasma cell as having the regulated or default RNA processing
environment. In a survey of µ gene expression in non-B-cell lines,
the pA/splice (µs/µm) ratio varied widely but was more similar to
that seen in a plasma cell line than to that seen in a B-cell line
(25). However, more recently we have examined several µ gene variants in a nonlymphoid cell line and have obtained different
results; some µ genes were processed more like a plasma cell, while
some were processed more like a B cell (23). In the current
study, transgene mRNA expression in different mouse tissues is shown to
vary over a range that overlaps both resting and LPS-activated B-cell
expression patterns. Thus, the paradigm of regulated and default RNA
processing patterns is probably not appropriate for the µ gene, where
both alternate RNAs are always coexpressed and it is the ratio of the
two that is modulated. Changes in the components for splicing,
cleavage-polyadenylation, or both, relative to each other, are
likely to be the essential features of µ regulation. Thus, each cell
type, both lymphoid and nonlymphoid, may be expected to contain a
characteristic concentration of processing factors; these
concentrations change, relative to each other, during B-lymphocyte
maturation.
 |
ACKNOWLEDGMENTS |
We thank Brian Pittner and Suzanna Reid for advice on B-cell
preparation and Teresa Roberts for the purified antibodies used in the
B-cell preparation procedure.
This work was supported by grants MCB-9507513 and
MCB-9106130 from the National Science Foundation (to M.L.P.)
and PHS grant GM-45253 (to B.T.S.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology and Laboratory Medicine, University of Kentucky College of Medicine, 800 Rose St., Lexington, KY 40536-0093. Phone: (606) 257-5478. Fax: (606) 323-2094. E-mail:
mlpete01{at}pop.uky.edu.
Present address: T.H. Morgan School of Biological Sciences,
University of Kentucky, Lexington, KY 40506.
 |
REFERENCES |
| 1.
|
Alt, F. W.,
A. L. M. Bothwell,
M. Knapp,
E. Siden,
E. Mather,
M. Koshland, and D. Baltimore.
1980.
Synthesis of secreted and membrane-bound immunoglobulin mu heavy chains is directed by mRNAs that differ at their 3' ends.
Cell
20:293-301[Medline].
|
| 2.
|
Belayew, A., and S. M. Tilghman.
1982.
Genetic analysis of -fetoprotein synthesis in mice.
Mol. Cell. Biol.
2:1427-1435[Abstract/Free Full Text].
|
| 3.
|
Bieberich, C.,
G. Scangos,
K. Tanaka, and G. Jay.
1986.
Regulated expression of a murine class I gene in transgenic mice.
Mol. Cell. Biol.
6:1339-1342[Abstract/Free Full Text].
|
| 4.
| Bruce, S. R., and M. L. Peterson.
Unpublished data.
|
| 5.
|
Ceredig, R.,
J. W. Lowenthal,
M. Nabholz, and H. R. MacDonald.
1985.
Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells.
Nature
314:98-100[Medline].
|
| 6.
|
Crenshaw, E. B. I.,
A. F. Russo,
L. W. Swanson, and M. G. Rosenfeld.
1987.
Neuron-specific alternative RNA processing in transgenic mice expressing a metallothionein-calcitonin fusion gene.
Cell
49:389-398[Medline].
|
| 7.
|
DeBenedette, M., and E. C. Snow.
1991.
Induction and regulation of casein kinase II during B lymphocyte activation.
J. Immunol.
147:2839-2845[Abstract].
|
| 8.
|
Early, P.,
J. Rogers,
M. Davis,
K. Calame,
M. Bond,
R. Wall, and L. Hood.
1980.
Two mRNAs can be produced from a single immunoglobulin µ gene by alternative RNA processing pathways.
Cell
20:313-319[Medline].
|
| 9.
|
Edwalds-Gilbert, G., and C. Milcarek.
1995.
Regulation of poly(A) site use during mouse B-cell development involves a change in the binding of a general polyadenylation factor in a B-cell stage-specific manner.
Mol. Cell. Biol.
15:6420-6429[Abstract].
|
| 10.
|
Evans, G. A.,
D. H. Margulies,
B. Shykind,
J. G. Seidman, and K. Ozato.
1984.
Exon shuffling: mapping polymorphic determinants on hybrid mouse transplantation antigens.
Nature
300:755-757.
|
| 11.
|
Gerster, T.,
D. Picard, and W. Schaffner.
1986.
During B-cell differentiation enhancer activity and transcription rate of immunoglobulin heavy chain genes are high before mRNA accumulation.
Cell
45:45-52[Medline].
|
| 12.
|
Grosveld, F., and G. Kollias (ed.).
1992.
.
Transgenic mice, 2nd ed.
Academic Press Inc., San Diego, Calif.
|
| 13.
|
Hogan, B.,
F. Costantini, and E. Lacy.
1986.
.
Manipulating the mouse embryo: a laboratory manual.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 14.
|
Hogbom, E.,
I.-L. Matrensson, and T. Leanderson.
1987.
Regulation of immunoglobulin transcription rates and mRNA processing in proliferating normal B lymphocytes by activators of protein kinase C.
Proc. Natl. Acad. Sci. USA
84:9135-9139[Abstract/Free Full Text].
|
| 15.
|
Hyman, R.,
P. Ralph, and S. Sarkar.
1972.
Cell-specific antigens and immunoglobulin synthesis of murine myeloma cells and their variants.
J. Natl. Cancer Inst.
48:173-184.
|
| 16.
|
Kelley, D. E., and R. P. Perry.
1986.
Transcriptional and post-transcriptional control of immunoglobulin mRNA production during B lymphocyte development.
Nucleic Acids Res.
14:5431-5447[Abstract/Free Full Text].
|
| 17.
|
Kim, K. J.,
C. Kanellopoulos-Langevin,
R. M. Merwin,
D. H. Sachs, and R. Asofsky.
1979.
Establishment and characterization of BALB/c lymphoma lines with B cell properties.
J. Immunol.
122:549-553[Abstract/Free Full Text].
|
| 18.
|
Laird, P. W.,
A. Zijderveld,
K. Linders,
M. A. Rudnicki,
R. Jaenisch, and A. Berns.
1991.
Simplified mammalian DNA isolation procedure.
Nucleic Acids Res.
19:4293[Free Full Text].
|
| 19.
|
Lamson, G., and M. E. Koshland.
1984.
Changes in J chain and µ chain RNA expression as a function of B cell differentiation.
J. Exp. Med.
160:877-892[Abstract/Free Full Text].
|
| 20.
|
Lassman, C. R.,
S. Matis,
B. L. Hall,
D. L. Toppmeyer, and C. Milcarek.
1992.
Plasma cell-regulated polyadenylation at the Ig 2b secretion-specific poly(A) site.
J. Immunol.
148:1251-1260[Abstract].
|
| 21.
|
Lutz, C. S.,
K. G. Murthy,
N. Schek,
J. P. O'Connor,
J. P. Manley, and J. C. Alwine.
1996.
Interaction between the U1 snRNP-A protein and the 160 kD subunit of cleavage-polyadenylation specificity factor increases polyadenylation efficiency in vitro.
Genes Dev.
10:325-337[Abstract/Free Full Text].
|
| 22.
|
Mattox, W.,
L. Ryner, and B. S. Baker.
1992.
Autoregulation and multifunctionality among trans-acting factors that regulate alternative pre-mRNA processing.
J. Biol. Chem.
267:19023-19026[Free Full Text].
|
| 23.
| Peterson, M. Unpublished data.
|
| 24.
|
Peterson, M. L.
1992.
Balanced efficiencies of splicing and cleavage-polyadenylation are required for µs and µm mRNA regulation.
Gene Expr.
2:319-327[Medline].
|
| 25.
|
Peterson, M. L.
1994.
Regulated immunoglobulin (Ig) RNA processing does not require specific cis-acting sequences: non-Ig genes can be alternatively processed in B cells and plasma cells.
Mol. Cell. Biol.
14:7891-7898[Abstract/Free Full Text].
|
| 26.
|
Peterson, M. L.
1994.
RNA processing and the expression of immunoglobulin genes, p. 321-342. In
E. C. Snow (ed.), Handbook of B and T lymphocytes.
Academic Press, San Diego, Calif.
|
| 27.
|
Peterson, M. L.,
M. B. Bryman,
M. Peiter, and C. Cowan.
1994.
Exon size affects competition between splicing and cleavage-polyadenylation in the immunoglobulin µ gene.
Mol. Cell. Biol.
14:77-86[Abstract/Free Full Text].
|
| 28.
|
Peterson, M. L.,
E. R. Gimmi, and R. P. Perry.
1991.
The developmentally regulated shift from membrane to secreted µ mRNA production is accompanied by an increase in cleavage-polyadenylation efficiency but no measurable change in splicing efficiency.
Mol. Cell. Biol.
11:2324-2327[Abstract/Free Full Text].
|
| 29.
|
Peterson, M. L., and R. P. Perry.
1989.
The regulated production of µm and µs mRNA is dependent on the relative efficiencies of µs poly(A) site usage and the Cµ4-to-M1 splice.
Mol. Cell. Biol.
9:726-738[Abstract/Free Full Text].
|
| 30.
|
Rogers, J.,
P. Early,
C. Carter,
K. Calame,
M. Bond,
L. Hood, and R. Wall.
1980.
Two mRNAs with different 3' ends encode membrane-bound and secreted forms of immunoglobulin µ chain.
Cell
20:303-312[Medline].
|
| 31.
|
Schmiedeberg, P.,
L. Biempica, and M. J. Czaja.
1993.
Timing of protooncogene expression varies in toxin-induced liver regeneration.
J. Cell. Physiol.
154:294-300[Medline].
|
| 32.
|
Spear, B. T.
1994.
Mouse -fetoprotein gene 5' regulatory elements are required for postnatal regulation by raf and Rif.
Mol. Cell. Biol.
14:6497-6505[Abstract/Free Full Text].
|
| 33.
|
Takagaki, Y.,
R. L. Seipelt,
M. L. Peterson, and J. L. Manley.
1996.
The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation.
Cell
87:941-952[Medline].
|
| 34.
|
Wassarman, K. M., and J. A. Steitz.
1993.
Association with terminal exons in pre-mRNAs: a new role for the U1 snRNP?
Genes Dev.
7:647-659[Abstract/Free Full Text].
|
| 35.
|
Wetzel, G. D., and J. R. Kettman.
1981.
Activation of murine B lymphocytes. III. Stimulation of B lymphocyte clonal growth with lipopolysaccharide and dextran sulfate.
J. Immunol.
126:723-728[Abstract].
|
| 36.
|
Yuan, D., and P. W. Tucker.
1984.
Transcriptional regulation of µ- heavy chain locus in normal murine B lymphocytes.
J. Exp. Med.
160:564-583[Abstract/Free Full Text].
|
Mol Cell Biol, February 1998, p. 1042-1048, Vol. 18, No. 2
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Peterson, M. L., Bingham, G. L., Cowan, C.
(2006). Multiple features contribute to the use of the immunoglobulin m secretion-specific poly(a) signal but are not required for developmental regulation.. Mol. Cell. Biol.
26: 6762-6771
[Abstract]
[Full Text]
-
Perincheri, S., Dingle, R. W. C., Peterson, M. L., Spear, B. T.
(2005). Hereditary persistence of {alpha}-fetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene. Proc. Natl. Acad. Sci. USA
102: 396-401
[Abstract]
[Full Text]
-
Ellis, P. D., Smith, C. W. J., Kemp, P.
(2004). Regulated Tissue-specific Alternative Splicing of Enhanced Green Fluorescent Protein Transgenes Conferred by {alpha}-Tropomyosin Regulatory Elements in Transgenic Mice. J. Biol. Chem.
279: 36660-36669
[Abstract]
[Full Text]
-
Phillips, C., Pachikara, N., Gunderson, S. I.
(2004). U1A Inhibits Cleavage at the Immunoglobulin M Heavy-Chain Secretory Poly(A) Site by Binding between the Two Downstream GU-Rich Regions. Mol. Cell. Biol.
24: 6162-6171
[Abstract]
[Full Text]
-
BRUCE, S. R., DINGLE, R.W. C., PETERSON, M. L.
(2003). B-cell and plasma-cell splicing differences: A potential role in regulated immunoglobulin RNA processing. RNA
9: 1264-1273
[Abstract]
[Full Text]
-
Peterson, M. L., Bertolino, S., Davis, F.
(2002). An RNA Polymerase Pause Site Is Associated with the Immunoglobulin {micro}s Poly(A) Site. Mol. Cell. Biol.
22: 5606-5615
[Abstract]
[Full Text]
-
Fehniger, T. A., Suzuki, K., Ponnappan, A., VanDeusen, J. B., Cooper, M. A., Florea, S. M., Freud, A. G., Robinson, M. L., Durbin, J., Caligiuri, M. A.
(2001). Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype CD8+ T Cells. JEM
193: 219-232
[Abstract]
[Full Text]
-
Coyle, J. H., Lebman, D. A.
(2000). Correct Immunoglobulin {alpha} mRNA Processing Depends on Specific Sequence in the C{alpha}3-{alpha}M Intron. J. Immunol.
164: 3659-3665
[Abstract]
[Full Text]
-
Zhao, J., Hyman, L., Moore, C.
(1999). Formation of mRNA 3' Ends in Eukaryotes: Mechanism, Regulation, and Interrelationships with Other Steps in mRNA Synthesis. Microbiol. Mol. Biol. Rev.
63: 405-445
[Abstract]
[Full Text]
-
Martincic, K., Campbell, R., Edwalds-Gilbert, G., Souan, L., Lotze, M. T., Milcarek, C.
(1998). Increase in the 64-kDa subunit of the polyadenylation/cleavage stimulatory factor during the G0 to S phase transition. Proc. Natl. Acad. Sci. USA
95: 11095-11100
[Abstract]
[Full Text]